Pharma Stock Hits Record High on Newest Weight-Loss Drug

Novo Nordisk A/S (NYSE:NVO) stock is gapping to record highs today, after the pharmaceutical company reported positive phase 1 trial results for its experimental weight-loss drug, amycretin. Showing higher weight loss than its already rabidly popular Wegovy, the drug is fully in the ring of contenders, with phase 2 results due out early 2026. At last glance, NVO was up 9.2% at $136.23, and earlier peaked at$136.50. The stock has finished 10 of the last 12 weeks higher, and sports a 92% year-over-year gain. ...